<DOC>
	<DOCNO>NCT02080767</DOCNO>
	<brief_summary>The purpose clinical protocol treat individual Tecovirimat exposure orthopox virus .</brief_summary>
	<brief_title>Tecovirimat ( ST-246 ) Treatment Orthopox Virus Exposure</brief_title>
	<detailed_description />
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Monkeypox</mesh_term>
	<criteria>DoDaffiliated personnel ( include US civilian employee , contractor US personnel dependent , well allied military force local national ) age , breastfeeding Has expose infect orthopox virus ( ie , variola ( smallpox ) , vaccinia , monkeypox , cowpox ) OR Has develop serious complication vaccinia vaccination ( eg , eczema vaccinatum , progressive vaccinia , generalize vaccinia severe persistent , select case inadvertent inoculation due severe pain related mucosal involvement , ocular involvement ) result vaccination , secondary transmission , exposure Is available clinical followup duration treatment followup period Must able swallow capsule Has hypersensitivity tecovirimat Unable unwilling cooperate requirement treatment protocol Breastfeeding patient . Note breastfeed female counsel tecovirimat study breastfeed woman may opt cease breastfeed duration treatment least 30 day last dose drug thus eligible enrollment . Women choose continue breastfeed enrolled treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>